Capecitabine
Capecitabine: Understanding its Impact, Recognizing Problems, and Ways to Improve
Capecitabine is an orally-administered chemotherapeutic agent primarily used in the treatment of metastatic breast cancer and colorectal cancer.It is a prodrug that gets enzymatically converted to fluorouracil (5-FU) within tumor cells.Once converted, 5-FU inhibits DNA synthesis and slows the growth of tumor tissue.
Impact of Gene Variant
DPD (Dihydropyrimidine Dehydrogenase) gene plays a crucial role in the metabolism of capecitabine.Variations in the DPD gene can affect the conversion of capecitabine to its active form (5-FU).Patients with DPD deficiency may experience severe toxicity due to impaired drug metabolism.
Ways to Recognize Problems
- Genetic testing: Assessing DPD gene variants can help identify patients at risk of adverse effects.
- Monitoring: Regular blood tests to measure drug levels and assess side effects.
- Patient history: Understanding prior reactions to fluoropyrimidines (like 5-FU) helps predict capecitabine response.
